Thomas Andrew Gaziano, M.D.
This page shows the publications co-authored by Thomas Gaziano and Ankur Pandya.
Cost-effectiveness of Financial Incentives for Patients and Physicians to Manage Low-Density Lipoprotein Cholesterol Levels. JAMA Netw Open. 2018 09 07; 1(5):e182008.
Validation of a Cardiovascular Disease Policy Microsimulation Model Using Both Survival and Receiver Operating Characteristic Curves. Med Decis Making. 2017 10; 37(7):802-814.
Cost-effectiveness of Statin Therapy for ASCVD--Reply. JAMA. 2015 Nov 24; 314(20):2191-2.
Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease. JAMA. 2015 Jul 14; 314(2):142-50.
Who needs laboratories and who needs statins?: comparative and cost-effectiveness analyses of non-laboratory-based, laboratory-based, and staged primary cardiovascular disease screening guidelines. Circ Cardiovasc Qual Outcomes. 2014 Jan; 7(1):25-32.
A comparative assessment of non-laboratory-based versus commonly used laboratory-based cardiovascular disease risk scores in the NHANES III population. PLoS One. 2011; 6(5):e20416.
Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States. Am Heart J. 2019 08; 214:77-87.
Comparison of Nonblood-Based and Blood-Based Total CV Risk Scores in Global Populations. Glob Heart. 2016 Mar; 11(1):37-46.e2.
Cardiovascular Disease Screening By Community Health Workers Can Be Cost-Effective In Low-Resource Countries. Health Aff (Millwood). 2015 Sep; 34(9):1538-45.
Increasing Prescription Length Could Cut Cardiovascular Disease Burden And Produce Savings In South Africa. Health Aff (Millwood). 2015 Sep; 34(9):1578-85.
More americans living longer with cardiovascular disease will increase costs while lowering quality of life. Health Aff (Millwood). 2013 Oct; 32(10):1706-14.
Comparative assessment of absolute cardiovascular disease risk characterization from non-laboratory-based risk assessment in South African populations. BMC Med. 2013 Jul 24; 11:170.
Guidance for a causal comparative effectiveness analysis emulating a target trial based on big real world evidence: when to start statin treatment. J Comp Eff Res. 2019 09; 8(12):1013-1025.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.